The association between malignant hyperthermia (MH) and neuromuscular disorders is controversial. An association between MH and Duchenne muscular dystrophy, a common and lethal disorder caused by deficiency of dystrophin, has been reported sporadically but is still not proved. To examine this problem, we performed halothane and caffeine in vitro contracture tests on skeletal muscles from dystrophin deficient mdx mice, an animal model for human Duchenne muscular dystrophy. As neither halothane nor caffeine triggered abnormal responses in mdx muscles, we conclude that dystrophin deficiency per se is not the primary cause of MH-like crises, as reported for patients with Duchenne muscular dystrophy. (Br.
On the basis of sporadic clinical reports 1 2 an association between malignant hyperthermia (MH) has been described and several neuromuscular disorders, such as central core disease, King-Denborough syndrome, several myotonic disorders and several forms of muscular dystrophies, including Duchenne muscular dystrophy. Duchenne muscular dystrophy is an X-linked lethal muscle disorder (with an incidence of approximately 1 in 3500 male births) caused by lack of, or reduction in, dystrophin, a 427-kDa spectrin-like protein which is expressed at the inner surface of the plasma membranes of skeletal and cardiac muscle fibres. 3 In the mouse model for Duchenne muscular dystrophy (mdx mutant mouse), dystrophin deficiency causes only mild myopathy without clinically overt symptoms. In both conditions, human Duchenne muscular dystrophy and murine mdx, defective intracellular calcium homeostasis, leading to increased sarcoplasmic calcium concentrations, is considered to arise from defective muscle fibre membranes caused by deficiency of dystrophin. 1 3 Defective sarcoplasmic calcium homeostasis is also thought to be the pathophysiological basis of MH, 1 2 4 5 a hypermetabolic crisis, characterized by a rapid increase in temperature, hypercontractility and rigidity of muscles, in addition to respiratory and metabolic acidosis. 1 2 In susceptible patients, MH is triggered by inhalation anaesthetic agents (e.g. halothane) and depolarizing neuromuscular blocking agents (e.g. suxamethonium). 2 4 Although in some MH pedigrees, mutations within the ryanodine receptor gene (RYR1) 4 5 encoding a calcium regulatory membrane protein have been identified, the molecular basis is not clear for the majority of MH patients. 1 Thus defective sarcoplasmic calcium homeostasis is common to both dystrophin deficiency and RYR1 mutations. Because Duchenne muscular dystrophy is one of the most common and severe neuromuscular disorders, we carried out this study in order to determine if dystrophin deficiency and concomitant defective calcium homeostasis leads to increased MH susceptibility. For this purpose we performed in vitro contracture tests (IVCT) on dystrophin deficient mdx muscle and on normal mouse muscle.
Methods and results
Ten male C57BL /10ScSnHimmdx mice and 10 male normal mice (C57BL/10ScSnHim) were killed by cervical dislocation at the age of 10 weeks. Dystrophin status of mdx and normal mouse muscle was determined by immunohistochemistry and by Western blotting, using a dystrophin specific polyclonal antiserum raised in sheep, directed against the 60-kDa dystrophin fusion protein. 3 Immediately after cervical dislocation, both extensor digitorum longus (EDL) muscles were excised and immersed in modified Krebs-Ringer solution which was gassed continuously with 95% oxygen and 5% carbon dioxide. IVCT were performed, exposing one muscle to halothane and the contralateral muscle to caffeine. In order to accommodate for the small mouse muscles (approximate weight 0.02 g), the standard procedure of the European Malignant Hyperthermia Group 6 was modified slightly (pre-drug resting tension approximately 1 g). Muscle viability was tested by electrical stimulation (repetition rate 0.2 Hz; pulse width 1 ms; constant current approximately 80 mA). Halothane was added to the gas-flow to achieve a final concentration of 0.11, 0.22, 0.44 and 0.66 mmol litre
91
, using an agent-specific vaporizer (Vapor 3.1, Dräger, Germany). Caffeine concentrations were increased cumulatively (0.5, 1, 2, 3 and 4 mmol litre
). When, after a stabilization period (ജ20 min), resting tension did not decrease by more than 0.04 mN min
, halothane and caffeine tests were started. Contractile force was evaluated from the chart records by calculating the respective drug-induced increase, that is the difference between the highest contracture which was observed within 3 min after drug administration and pre-drug force of contraction. At the end of the test, the viability of the muscles was tested using caffeine concentrations of 32 mmol litre
. As all muscles tested responded with tetanic contractures they were considered viable (tables 1, 2).
EFFECT OF HALOTHANE IVCT ON MDX (N:10) AND NORMAL MUSCLES (N:10) In mdx muscles there were no dose-dependent increases in muscle contractures after adding halothane (table 1) .
In EDL muscles from normal mice, before and after adding the drugs, transient and doseindependent increases in contractile force were recorded in three of 10 muscles exposed to halothane. However, within 1-3 min, the contractures re-stabilized at pre-drug baseline values. Apart from these transient contractures there were no increases produced by halothane.
At the end of the experiments muscle viability was tested in both groups by adding caffeine 32 mmol litre
. All muscles responded with tetanic contractures. In these tests mdx muscles responded with an average increase of 3.2 g, while control muscles responded with an average increase of 5.7 g (table 1).
EFFECT OF CAFFEINE IVCT ON MDX (N:8) AND NORMAL MUSCLES (N:10) The caffeine test was carried out on eight of 10 mdx muscle specimens and no dose-dependent increases in muscle contracture were observed (table 2).
In five of 10 control muscles, transient and doseindependent increases in contractile force were recorded, as described above.
Tetanic contractures produced by addition of caffeine 32 mmol litre 91 at the end of the experiments Table 2 Caffeine in vitro contracture test using EDL muscles from dystrophin deficient mdx mice (mdx) and from normal mice (control). All values for twitch height and contracture force are in grams. Responses to cumulative administration of caffeine 0.5-4.0 mmol litre 91 are maximum increases above pre-drug levels. These responses are indicated as negative (neg.) or transient, dose-independent contractures, which decreased to baseline within 1-3 min; >:outside the range of recording. EDL muscles from mdx mice Nos 4 and 9 were not reliable (nr) because the baseline did not stabilize within 20 min of the pre-drug period Pre-drug twitch height ;Caffeine (0. were demonstrable in both mdx and normal muscle specimens. The mdx muscles responded with an average increase of 2.1 g while the control muscles responded with an average increase of 4.2 g (table 2) .
Comment
We have used the dystrophin deficient mdx mouse, a valid and commonly accepted animal model for Duchenne muscular dystrophy, to study if dystrophin deficiency in human Duchenne muscular dystrophy is causative for the MH-like crises which have been observed sporadically in patients with Duchenne muscular dystrophy. 1 2 Using an in vitro assay (i.e. IVCT) as recommended by the European MH Group 6 for MH diagnosis, we found no abnormal reactions in mdx muscles after exposure to either halothane or caffeine. These data strongly indicate that there is no increased MH susceptibility in dystrophin deficient mdx mouse muscle. Normal and dystrophic mouse muscles fulfilled the viability criteria as all muscles tested responded to the addition of caffeine 32 mmol litre 91 at the end of the experiments with tetanic contractures. Moreover, muscles responded to electrical stimulation by reproducible twitches in the respective IVCT experiments. For mdx muscles we observed relatively small twitch responses during the pre-drug period and relatively small contractile forces after adding caffeine 32 mmol litre 91 compared with normal mouse muscles. This phenomenon is consistent with the findings of Coulton and colleagues that mdx muscle shows less twitch and tetanic tension compared with normal mouse muscle. 7 Transient, short contractures, as occurred in normal mouse muscle (three of 10 muscles in the halothane test (table 1) , five of 10 muscles in the caffeine test (table 2)) can also be seen sporadically in human muscles which are finally diagnosed as MH negative (MHN) (H. Gilly, unpublished data). Although it is difficult to define a threshold for normal mouse muscle we did not observe the phenomenon of spontaneous contractures in mdx muscle, indicating that mdx muscle fulfilled the "normality criteria" with respect to the IVCT protocol which was designed for human muscle samples. In this context we cannot determine if transient contractures are specific for the normal C57BL/10 mouse strain used. As neither halothane nor caffeine induced abnormal prolonged contractures in any normal or dystrophic muscle tested, we conclude that dystrophin deficiency per se is not the primary cause of increased MH susceptibility.
Defective calcium homeostasis, which is common to human Duchenne muscular dystrophy and mdx muscle, is considered to play a crucial pathophysiological role in MH. 2 4 5 This is corroborated by the finding that missense mutations affecting the calcium regulatory domain of the ryanodine receptor (RYR1) are associated with MH in humans and in pigs. 1 4 5 However, despite defective calcium homeostasis in dystrophin deficient mdx muscle, we did not observe any MH related changes during halothane-caffeine IVCT. Our findings cannot exclude the possibility that in human Duchenne muscular dystrophy muscle which is more severely affected by dystrophic changes and necrotic events compared with mdx muscle, there might be a threshold dependent mechanism with respect to increased intracellular calcium concentrations and consequent MH susceptibility. We conclude that mechanisms other than dystrophin deficiency should be considered in the aetiology of increased MH susceptibility in human Duchenne muscular dystrophy.
